Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 1%.
The iShares Biotechnology ETF (IBB) fell 2.7%.
In corporate news, Bausch + Lomb (BLCO) shares fell 3.5%. The company said late Thursday that results from a phase 2 trial assessing BL1107 in people with glaucoma showed the study did not meet its primary endpoint of replicating visual function improvements seen in a smaller phase 1/2a trial.
Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Separately, Pfizer's (PFE) vaccine disputes with Poland and Romania continue, now extending to the countries' air traffic agencies, Bloomberg reported. Pfizer shares were up 0.1%.
Cosmos Health (COSM) shares jumped 10% after it said Friday that it has launched a subscription-based purchasing model for its consumer health brands.